Charles Bennett to Prostate-Specific Antigen
This is a "connection" page, showing publications Charles Bennett has written about Prostate-Specific Antigen.
Connection Strength
2.418
-
Editorial Comment. Urology. 2018 08; 118:125-126.
Score: 0.562
-
What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening? Clin Genitourin Cancer. 2017 12; 15(6):e977-e985.
Score: 0.523
-
Editorial comment. Urology. 2012 Sep; 80(3):563.
Score: 0.374
-
Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer". Arch Intern Med. 2010 Aug 09; 170(15):1397-9.
Score: 0.327
-
Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology. 2006 Jul; 68(1):89-93.
Score: 0.246
-
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5.
Score: 0.113
-
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60.
Score: 0.100
-
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar; 75(3):623-9.
Score: 0.076
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.065
-
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5.
Score: 0.022
-
Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000; 4(3):259-63;discussion 265.
Score: 0.010